3050 Spruce Street, St. Louis, MO 63103 USA Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757 email: techservice@sial.com sigma-aldrich.com

# **Product Information**

## Anti-EDEM2 (C-terminal)

produced in rabbit, affinity isolated antibody

Product Number E1782

## **Product Description**

Anti-EDEM2 (C-terminal) is produced in rabbit using as immunogen a synthetic peptide corresponding to a sequence at C-terminal of human EDEM2 (GeneID: 55741), conjugated to KLH. The corresponding sequence is identical in mouse and rat EDEM2. The antibody is affinity-purified using the immunizing peptide immobilized on agarose.

Anti-EDEM2 (C-terminal) recognizes human and rat EDEM2. The antibody may be used in various immunochemical techniques including immunoblotting (~70 kDa) and immunofluorescence. Detection of the EDEM2 band by immunoblotting is specifically inhibited with the immunizing peptide.

EDEM2 (ER degradation-enhancing alphamannosidase-like protein 2), a stress-regulated mannosidase-like protein, targets misfolded glycoproteins for degradation in an N-glycan dependent manner. Proteins that fail to fold in the ER are transferred from the ER to the cytosol, where they are destroyed by the ubiquitin-proteasome system. Quality control in the ER is regulated by productive folding and ER-associated degradation (ERAD) mechanisms. Accelerated refolding and degradation of unfolded proteins are induced in response to ER stress by a transcriptional program termed the unfolded protein response (UPR).

Three EDEM homologues, EDEM1, EDEM2 and EDEM3 have been identified, which are transcriptionally upregulated upon ER stress by the activated IRE1/Xbp-1 branch.<sup>5</sup> EDEM2, similarly to EDEM1, is localized to the ER, mainly as a soluble glycoprotein, interacts with calnexin and lacks mannosidase activity.<sup>1,2,6</sup> Overexpression of EDEM2 accelerates ERAD by promoting the release of terminally misfolded glycoproteins from the calnexin cycle, without affecting the rate of degradation of non-glycosylated polypeptides or the maturation of model secretory proteins.<sup>2</sup>

## Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide as a preservative.

Antibody concentration: ~1.0 mg/mL

#### **Precautions and Disclaimer**

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

## Storage/Stability

For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

## **Product Profile**

 $\frac{Immunoblotting}{0.5\text{-}1.0~\mu g/mL} \ is \ recommended \ using \ whole \ extracts \ of \ human \ HepG2 \ and \ rat \ NRK \ cells.$ 

<u>Note</u>: In order to obtain best results in various techniques and preparations, it is recommended to determine optimal working dilutions by titration

### References

- Mast, S.W. et al., Glycobiology, 15, 421-436 (2005).
- Olivari, S. et al., J. Biol. Chem., 280, 2424-2428 (2005).
- 3. Kostova, Z., and Wolf, D.H., *EMBO J.*, **22**, 2309-2317 (2003).
- 4. Oda, Y. et al., J. Cell Biol., 172, 383-393 (2006).
- Ni, M., and Lee, A.S., FEBS Lett., 581, 3641-3651 (2007).
- 6. Oda, Y. et al., Science, 299, 1394-1397 (2003).

VS,ST,BR,PHC,MAM 01/19-1